Skip to main content

Market Overview

10 Healthcare Stocks Moving In Monday's Pre-Market Session

Share:

Gainers

  • ASLAN Pharmaceuticals, Inc. (NASDAQ: ASLN) shares increased by 80.6% to $6.90 during Monday's pre-market session. The market cap seems to be at $49.3 million. The most recent rating by H.C. Wainwright, on November 14, is at Buy, with a price target of $2.00.
  • Evofem Biosciences, Inc. (NASDAQ: EVFM) stock surged 39.0% to $8.49. The market cap stands at $237.1 million. The most recent rating by Cantor Fitzgerald, on October 16, is at Overweight, with a price target of $9.00.
  • Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) stock moved upwards by 27.4% to $5.62. The market cap seems to be at $55.2 million. The most recent rating by Ladenburg Thalmann, on September 11, is at Buy, with a price target of $7.00.
  • Diffusion Pharmaceuticals, Inc. (NASDAQ: DFFN) stock rose 9.5% to $0.45. The market value of their outstanding shares is at $3.9 million.
  • Ocugen, Inc. (NASDAQ: OCGN) stock moved upwards by 8.0% to $0.41. The market cap stands at $19.7 million. The most recent rating by Chardan Capital, on November 27, is at Buy, with a price target of $2.00.
  • Onconova Therapeutics, Inc. (NASDAQ: ONTX) stock surged 5.8% to $0.20. The market value of their outstanding shares is at $4.3 million.
  • Clovis Oncology, Inc. (NASDAQ: CLVS) stock surged 3.5% to $15.45. The market cap seems to be at $173.7 million. The most recent rating by Evercore ISI Group, on November 19, is at In-Line, with a price target of $8.00.
  • Amarin Corp, Inc. (NASDAQ: AMRN) stock rose 1.6% to $21.61. The market cap stands at $5.8 billion. The most recent rating by Oppenheimer, on November 20, is at Underperform, with a price target of $7.00.

 

Losers

  • Biogen, Inc. (NASDAQ: BIIB) shares fell 1.4% to $295.55 during Monday's pre-market session. The market value of their outstanding shares is at $53.8 billion. The most recent rating by Baird, on December 02, is at Underperform, with a price target of $250.00.
  • GlaxoSmithKline, Inc. (NYSE: GSK) stock fell 0.9% to $45.09. The market value of their outstanding shares is at $113.8 billion. According to the most recent rating by UBS, on November 21, the current rating is at Buy.
 

Related Articles (AMRN + ASLN)

View Comments and Join the Discussion!

Posted-In: Healthcare Stocks Pre-Market MoversNews Movers & Shakers Pre-Market Outlook Markets Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com